To the Members of

Concord Biotech Limited

Your Directors have pleasure in presenting the Integrated Annual Report along with the Audited Financial Statements of the Company for the financial year ended on March 31, 2026.

1. FINANCIAL AND OPERATIONAL HIGHLIGHTS

The financial results of the company for the year under review vis-à-vis previous financial year are as under:

The standalone and consolidated financial statement of the Company have been prepared in accordance with the Indian Accounting Standards ('Ind AS') as notified under the Companies (Indian Accounting Standard) Rules, 2015 as amended.

REVIEW OF OPERATIONS AND THE STATE OF COMPANY'S AFFAIRS

In FY26, your Company achieved a convincing revenue from operations of 1,05,507 lakhs, compared to 1,20,009 lakhs in FY25. This was primarily driven by the continued strength of our Active Pharmaceutical Ingredients (API) segment, which contributed 82,877 lakhs, accounting for 78.6% of total revenue. The Formulations segment contributed 22,630 lakhs, representing the remaining 21.4%. From a geographical perspective, domestic sales constituted 56,379 lakhs (53.4%), while exports contributed 49,128 lakhs (46.6%), reaffirming our strong global footprint and sustained international demand.

Other Income rose to 5273 lakhs in FY26 from 4445 lakhs in FY25, primarily driven by gains from strategic investments.

On a consolidated basis, the Company reported Net Profit of 25,922 Lakhs for the year ended

31 March 2026, as against 37,164 Lakhs in the previous financial year.

SHARE CAPITAL

During the year under review, there was no change in the Authorized and paid up share capital of the Company. The paid-up equity share capital of the Company as at March 31, 2026, stood at

10,46,16,204.

KEY DEVELOPMENTS AND STRATEGIC INITIATIVES

During the financial year ended March 31, 2026, the Company reached several notable milestones that underscore its dedication to innovation, regulatory excellence, and long-term sustainable growth.

• Strategic Expansion in the U.S. Market: Concord Biotech Limited made a strategic investment by acquiring a 75% equity stake in Stellon Biotech Inc., resulting in its classification as a subsidiary incorporated in the United States. This investment marked a significant step toward strengthening the Company's commercial presence in the U.S. market. Stellon Biotech Inc. is intended to serve as a dedicated platform for the marketing, distribution, and sale of Concord's products, thereby enhancing the Company's global reach and supporting its long-term growth strategy.

• Incorporation of a Wholly Owned Subsidiary:

Concord Biotech Limited incorporated Concord Lifegen Limited as a wholly owned subsidiary to strengthen its marketing, sales, and distribution capabilities. The subsidiary has been established to drive targeted commercial strategies, ensure regulatory compliance across domestic and international markets, manage logistics and customer support functions, and facilitate efficient reporting and governance aligned with the Company's business objectives.

REGULATORY APPROVALS

During the financial year 2025–26, Company's manufacturing facilities successfully underwent inspections conducted by various regulatory authorities, demonstrating the robustness of its quality and compliance systems.

• EU-GMP Certification for Dholka Facility:

Company's Dholka manufacturing facility successfully obtained European Union Good Manufacturing Practices (EU-GMP) certification, marking a significant milestone in its journey toward global regulatory excellence. This achievement reflects the strength of the Company's quality management systems and its unwavering commitment to maintaining the highest standards of quality, safety, and compliance. The certification enhances Concord's ability to serve customers across European Union markets and other highly regulated geographies, creating new opportunities for business expansion and reinforcing its global growth strategy.

• EU-GMP Certification for Limbasi Facility: Company's Limbasi manufacturing facility also received European Union Good Manufacturing Practices (EU-GMP) certification, further strengthening its regulatory credentials and manufacturing capabilities. This accomplishment demonstrates the Company's continued focus on operational excellence, adherence to stringent international quality standards, and readiness to meet the expectations of global regulatory authorities. The certification is expected to facilitate greater market access across the European Union and other regulated regions, supporting the Company's efforts to expand its international footprint and drive sustainable growth.

NAFDAC Inspection for Oral Solid Dosage (OSD) of Valthera Facility: Company successfully completed the NAFDAC (National Agency for Food and Drug Administration and Control) inspection for its Oral Solid Dosage (OSD) at Valthera facility. This achievement highlights the Company's strong commitment to maintaining the highest standards of quality, safety, and regulatory compliance across its manufacturing operations. It reflects the robustness of the Company's quality systems, its dedication to operational excellence, and its continued ability to meet the stringent requirements of international regulatory authorities, thereby strengthening its position in global pharmaceutical markets.

AWARDS AND RECOGNITIONS:

Hurun India Felicitation 2025: Concord Biotech was honored by Hurun India with the 'Pioneering Biopharmaceutical Innovation & Healthcare Ecosystem Award' in 2025. This prestigious recognition acknowledges the Company's outstanding contribution towards strengthening the healthcare ecosystem and driving innovation within the biopharmaceutical sector, particularly in Gujarat.

CHANGE IN THE NATURE OF BUSINESS, IF ANY:

There was no change in the nature of the Company's business during the financial year 2025–26.

. DIVIDEND

Your Directors have recommended final dividend of 7.55/- per equity share i.e. 755% on face value of 1/- each for the financial year ended on March 31, 2026. The dividend, if approved at the ensuing Annual General Meeting ('AGM'), will be paid to those members whose names appear in the Register of Members as on close of July 24, 2026. The total dividend payout will be approximately 7,898.52 Lakhs.

Pursuant to the provisions of Regulation 43A(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), the Board has formulated and adopted Dividend Distribution Policy which has been hosted on the website of the Company at https://www.concordbiotech. com/public/assets/pdf/Concord-Biotech-Limited-Dividend Distribution-Policy.pdf .

3. RESERVES

The Company has not transferred any amount from profit and loss to general reserve during the current financial year.

4. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Pursuant to Regulation 34 of the SEBI Listing Regulations, the Management Discussion and Analysis Report for the year under review, forms part of the Integrated Annual Report.

5. BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORTING

Pursuant to the provisions of Regulation 34 of the SEBI Listing Regulations, the Business Responsibility and Sustainability Report (BRSR), together with the Reasonable Assurance Report on BRSR Core attributes for the financial year ended March 31, 2026, constitutes an integral part of this Integrated Annual Report. The report outlines the Company's initiatives and performance across Environmental, Social, and Governance (ESG) parameters.

6. CORPORATE GOVERNANCE

The Company continues to remain committed to maintaining the highest standards of corporate governance. We believe that strong governance practices are essential for building a resilient, transparent, and responsible organization. Our governance framework is driven by robust policies, ethical leadership, and strict adherence to applicable laws and regulations across all levels of the organization. Our governance framework is designed to promote integrity, transparency, accountability, and fairness in all business dealings. These principles guide our decision-making processes and help us maintain investor confidence, enhance long-term shareholder value, and safeguard the interests of all stakeholders, including minority shareholders.

A separate section on Corporate Governance, in compliance with Regulation 34 of the SEBI Listing Regulations, forms part of this Report. A certificate from Mr. Ashish Shah, Practicing Company Secretary. confirming compliance with the conditions of Corporate Governance as prescribed under the SEBI Listing Regulations, 2015, is also annexed to this Report.

7. MATERIAL CHANGES AND COMMITMENTS

Pursuant to the provisions of the Companies Act, 2013, the following material change and commitment occurred between the end of the financial year and the date of this Report, which may have a bearing on the financial position of the Company: The Company has invested 66 Lakhs in Celliimune BiotechPrivateLimitedwiththeobjectiveofadvancing pioneering research in DNA engineering for cancer therapeutics and developing innovative alternatives to conventional chemotherapy. Consequent to this investment, Celliimune Biotech Private Limited has become a wholly owned subsidiary of the Company.

8. INTERNAL FINANCIAL CONTROL

The Company has established a comprehensive framework of internal financial controls designed to ensure the orderly and efficient conduct of its business operations. These controls encompass robust framework of internal financial controls that includes clearly defined policies, procedures, and systems—both manual and technology enabled. These controls are designed to ensure adherence to internal guidelines, safeguard the Company's assets, prevent and detect fraud and errors, and support the accuracy, completeness, and reliability of financial reporting. Continuous technological enhancements further strengthen the effectiveness and efficiency of these controls, aligning with evolving business needs and regulatory expectations.

Periodic internal audits are conducted by the Company's Internal Auditors to provide reasonable assurance on the effectiveness of the control systems and to recommend improvements aligned with industry best practices. The Audit Committee, comprising Independent Directors, regularly reviews key findings from both internal and statutory audits, monitors the implementation of corrective actions, and ensures timely mitigation of identified risks.

9. DETAILS OF SUBSIDIARY/JOINT VENTURES/ASSOCIATE COMPANIES

Below is the status of Subsidiary/Joint Ventures/Associate Companies as on March 31, 2026.

Pursuant to provisions of Section 129(3) of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014, a statement containing salient features of the financial statements in Form AOC-1 of Companies as above are enclosed as Annexure I of this report.

10. ANNUAL RETURN

Pursuant to the provisions of Section 92(3), Annual Return of the Company in Form MGT-7 for the financial year ended on March 31, 2026 is placed on the website of the Company and the same can be accessed at https://www.concordbiotech.com/investors .

11. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER SECTION 186 OF THE COMPANIES ACT, 2013

Details of investments made and/or loans or guarantees given and/or security provided, if any, are given in the notes to the Standalone and Consolidated financial statements which form part of this Integrated Annual Report.

12. DIRECTORS AND KEY MANAGERIAL PERSONNEL

As on March 31, 2026, the Board of Directors consisted of 9 Directors comprising of 7 Non-Executive Directors and 2 Executive Directors. Out of the 7 Non-Executive Directors, 5 are Independent Directors, including a Woman Independent Director. During the year under review, there were no changes in the Directors of the Company.

Mr. Lalit Sethi ceased to be the Chief Financial Officer of the Company with effect from January 5, 2026, pursuant to his resignation and Mr. Raviraj Karia was appointed as the Chief Financial Officer with effect from December 18, 2025.

Ms. Hina Patel resigned from the position of Company Secretary and Compliance Officer with effect from January 21, 2026. Thereafter, Mr. Paritosh Trivedi was appointed as the Company Secretary and Compliance Officer with effect from February 11, 2026.

Pursuant to the provisions of Section 152(6) and other applicable provisions, if any, of the Companies Act, 2013, including any statutory modification(s) or re-enactment(s) thereof for the time being in force, Mr. Ankur Vaid (DIN: 01857225), Director of the Company, retires by rotation at the 41 st Annual General Meeting and, being eligible, has offered himself for re-appointment. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors, at its meeting held on May 29, 2026, has recommended his re-appointment to the Members of the Company. Accordingly, the necessary resolution together with the requisite disclosures forms part of the Notice convening the ensuing Annual General Meeting.

13. MEETINGS OF THE BOARD OF DIRECTORS

During the year under review, the Board of Directors met five (5) times. Details of the Board meetings are provided in the Corporate Governance Report, which forms an integral part of this Annual Report. The interval between two consecutive Board meetings was within the timelines prescribed under the Companies Act, 2013 and the SEBI Listing Regulations.

14. INDEPENDENT DIRECTORS

Pursuant to Section 149(7) of the Companies Act, 2013 and Regulation 25(8) of the SEBI Listing Regulations, the Independent Directors of the Company have furnished declarations confirming that they meet the criteria of independence prescribed under the said section and regulation, read with Schedule IV of the Companies Act, 2013.

Further, in terms of Regulation 25(8) of the SEBI Listing Regulations, the Independent Directors have also confirmed that they are not aware of any circumstances or situations, which exist or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgement and without any external influence.

The Board is of the opinion that the Independent Directors possess integrity, requisite expertise, and relevant experience, including the necessary proficiency, to effectively discharge their duties and responsibilities as Independent Directors of the Company.

The Independent Directors held a separate meeting on February 10, 2026, in compliance with the requirements of Schedule IV of the Companies Act, 2013, Secretarial Standard-1 on Board Meetings issued by the Institute of Company Secretaries of India, and the SEBI Listing Regulations.

15. DEPOSITS

The Company has not accepted any deposits during the year under review, and no deposits were outstanding as on March 31, 2026. Further, there were no matured deposits remaining unpaid at the end of the year.

16. RELATED PARTY TRANSACTIONS

The particulars of contracts or arrangements entered into by the Company with related parties, as referred to under Section 188(1) of the Companies Act, 2013, including transactions carried out on an arm's length basis, are provided in Form AOC-2 enclosed as Annexure II to this Report.

17. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

Information as per Section 134(3)(m) of the Act read with Rule 8(3) of the Companies (Accounts) Rules, 2014 relating to conservation of energy, technology absorption, foreign exchange earnings and outgo is given in Annexure III to this Report.

18. DIRECTOR'S RESPONSIBILITY STATEMENT:

Pursuant to Section 134(3)(c) & (5) of the Companies Act, 2013 the Directors state that: i. In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures.

ii. Your Directors had selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period. iii. Your Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities. iv. Your Directors had prepared the attached Annual Accounts for the year ended on March 31, 2026 on a going concern basis. v. Your Directors had laid down internal financial controls to be followed by the Company and such internal financial controls are adequate and were operating effectively. vi Your Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

19. BOARD COMMITTEES:

Detailed information relating to the composition of the Audit Committee, Nomination and Remuneration Committee, CSR Committee, Stakeholders' Relationship Committee, Risk Management Committee of the Board and Management Committee, including the number of meetings held during the financial year 2025–26 and attendance of each member, as required under the Companies Act, 2013, is provided in the Corporate Governance Report forming part of this report.

20. PARTICULARS OF EMPLOYEES:

The disclosures required under Section 197(12) of the Act read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are provided in Annexure IV to this Report. The statement containing the names and other particulars of the top ten employees will be made available upon request addressed to the Company at complianceofficer@concordbiotech.com .

21. POLICY ON DIRECTORS' APPOINTMENT, REMUNERATION AND OTHER DETAILS

The Company has in place a Nomination and Remuneration Policy ('NRC Policy') which sets out the role of Nomination and Remuneration Committee (NRC), the criteria for appointment, qualifications, term/tenure etc. of Executive Directors & Independent Directors, annual performance evaluation, remuneration of Executive Directors, Non-Executive/ Independent Directors, Key Managerial Personnel & Senior Management, and the criteria to determine qualifications, positive attributes & independence of Director.

The NRC policy is available on the Company's website at https://concordbiotech.com/wp-content/ uploads/2025/09/17.-Concord-Biotech-Limited-Nomination-and-Remuneration-Policy.pdf

22. ANNUAL EVALUATION BY THE BOARD OF ITS OWN PERFORMANCE, ITS COMMITTEES AND INDIVIDUAL DIRECTORS:

The Board remains committed to fostering a diverse and inclusive leadership structure that reflects a wide range of perspectives, experiences, and expertise. We believe that diversity at the board level enhances governance quality, promotes balanced decision-making, and strengthens stakeholder confidence. During the year, we continued to advance our diversity agenda by ensuring representation across gender, professional backgrounds, and industry experience. This approach not only aligns with our corporate values but also supports our long-term strategic objectives and sustainable growth.

Pursuant to the provisions of the Companies Act, 2013 and Regulation 17 and Regulation 25 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a structured questionnaire was prepared after taking into consideration of the various aspects of the Board's functioning, Composition of the Board and Committees, culture, execution and performance of specific duties, obligation and governance. The performance evaluation of the Independent Directors was completed.

During the financial year under review, the Independent Directors met on February 10, 2026, inter alia, to discuss:

• Performance evaluation of Non-Independent Directors and Board of Directors as a whole;

• Performance evaluation of the Chairman of the Company;

• Evaluation of the quality of flow of information between the Management and Board for effective performance by the Board.

The Board of Directors expressed their satisfaction with the evaluation process.

23. CORPORATE SOCIAL RESPONSIBILITY:

The details of policy developed and implemented by the Company on Corporate Social Responsibility is available on website of Company at https://concordbiotech.com/csr-policy/ . Further Annual Report on CSR activities pursuant to Rule 8 of Companies (Corporate Social Responsibility policy) Rules, 2014 as amended is attached as Annexure V to this report.

24. AUDITORS

Statutory Auditors

The Statutory Auditors, M/s. BSR & Co. LLP, Chartered Accountants (ICAI Registration No. 101248W/W-100022), has been appointed for a period of five years till the conclusion of 44 th Annual General Meeting to be held in the financial year 2028-2029 on such remuneration as may be decided by the Board in consultation with the Statutory Auditors of the Company.

Explanation or comments by the Board of Directors of the Company on every qualification, reservation or adverse remark or disclaimer made by the Statutory Auditors in Audit report: The Auditors' Report on the financial statements of the Company for the Financial Year ended March 31, 2026, is unmodified i.e. it does not contain any qualification, reservation or adverse remark or disclaimer. The Auditors' Report is enclosed with the financial statements forming part of the Integrated Annual Report.

Cost Auditors

Pursuant to Section 148(1) of the Act, the Company has, during the year under review, maintained such cost accounts and records as specified by the Central Government. The said cost accounts and records for FY 2025–26 were audited by M/s. Dalwadi

& Associates, Cost Accountants (Firm Registration Number 000338), Cost Auditors of the Company.

The Board has re-appointed M/s. Dalwadi & Associates, Cost Accountants as Cost Auditors of the Company for conducting Cost Audit for FY 2026-27. A resolution seeking approval of the Shareholders to ratify the remuneration payable to the Cost Auditors for FY 2026-27 is provided in the Notice of the ensuing Annual General Meeting.

The Cost accounts and records as required to be maintained under Section 148 (1) of the Act are duly made and maintained by the Company.

Secretarial Auditors

M/s. Ashish Shah & Associates, Practicing Company Secretaries were appointed as the Secretarial Auditors of the Company from the conclusion of 40 th Annual General Meeting till the conclusion of 45 th Annual General Meeting of the Company pursuant to the provisions of Regulation 24A of SEBI Listing Regulations and Section 204 of the Companies Act, 2013 and rules made thereunder.

Pursuant to Section 204 of the Act, the Secretarial Audit Report for the Financial Year ended on March 31, 2026 provided by M/s. Ashish Shah & Associates, Practicing Company Secretaries is annexed herewith as Annexure-VI to this Report.

Explanation or comments by the Board of Directors on every qualification, reservation or adverse remark or disclaimer made by the Secretarial Auditors in Audit report: The Secretarial Auditor's Report to the Members does not contain any qualification or reservation which has any adverse effect on the functioning of the Company.

Internal Auditors

M/s Manubhai & Shah LLP, Chartered Accountants, Ahmedabad, were appointed as Internal Auditors for

FY 2025–26 and reappointed for FY 2026–27 by the Board on the Audit Committee's recommendation.

The Internal Auditor presents their report and findings on the internal audit of the Company to the Audit Committee on a quarterly basis. The scope and coverage of the internal audit are reviewed and approved by the Audit Committee to ensure alignment with the Company's risk management framework and operational priorities. The internal audit function continues to play a critical role in evaluating the effectiveness of internal controls, identifying areas for improvement, and supporting the Board in maintaining robust governance standards.

There are no qualifications or comments by the Statutory Auditors and Secretarial Auditors which require any explanation from the Directors.

During the year under review, no frauds were reported by the Auditors of the Company under Section 143(12) of the Companies Act, 2013 in their audit reports.

25. DETAILS OF SIGNIFICANT AND MATERIAL

ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE.

During the year under review, there were no significant and material orders passed by regulators, courts or tribunals impacting the going concern status and the Company's operations in future.

26. WHISTLE BLOWER POLICY AND VIGIL

MECHANISM:

In compliance with the provisions of the Companies Act, 2013, the Company has established a Whistle Blower Policy and Vigil Mechanism to enable employees and other stakeholders to report genuine concerns relating to unethical behavior, actual or suspected fraud, or violation of the Company's Code of Conduct and policies.

The Vigil Mechanism is overseen by the Audit Committee, which ensures that all concerns are addressed appropriately and in a fair and transparent manner. The Company has also put in place adequate safeguards against victimization of persons who raise concerns in good faith and has provided direct access to the Chairman of the Audit Committee for reporting matters involving the interests of employees and the Company.

The Whistle Blower Policy and Vigil Mechanism framework, as approved by the Board, is available on the Company's website at https://concordbiotech. com/wp-content/uploads/2026/04/4.-CBL_Whistle-Blower-Policy.pdf .

27. RISK MANAGEMENT POLICY OF THE

COMPANY:

The Company has structured risk management policy. The Risk management process is designed to safeguard the organization from various risks through adequate and timely actions. It is designed to anticipate, evaluate and mitigate risks in order to minimize its impact on the business. The potential risks are inventoried and integrated with the management process such that they receive the necessary consideration during decision making.

The Risk Management Policy of the Company is available on the website of the Company https://www.concordbiotech. com/public/assets/pdf/Concord-Biotech-Limited-Risk-Management-Policy.pdf

28. PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE

Your Company is committed to creating a safe and healthy work environment, where every employee is treated with respect and can work without fear of discrimination, prejudice, gender bias or any form of harassment at the workplace. The Company has in place a Prevention of Sexual Harassment (POSH) Policy which meets the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules thereunder. The Company has set up Internal Complaints Committee (ICC).

Details of POSH complaints during the year are as below:

29. MATERNITY BENEFITS

Your Company confirms compliance with the provisions of the Maternity Benefit Act, 1961, and the rules framed thereunder. Eligible women employees are provided maternity benefits in accordance with statutory requirements, including paid maternity leave.

30. HUMAN RESOURCES

The employees have played a major role in the performance of the Company over the years. They will continue to be the Company's pillars of strength in the years to come as proper training and exposure to the new products will be forthcoming. Industrial relations in the Company were amicable throughout the year under review.

31. INSURANCE

The Company's assets are comprehensively insured to mitigate financial exposure arising from a broad spectrum of operational, environmental, and other insurable risks, in alignment with our risk management framework and commitment to safeguarding stakeholder interests.

32. COMPLIANCEWITHSECRETARIALSTANDARDS

Your Directors confirm that, Company complies with applicable mandatory Secretarial Standards issued by the Institute of Company Secretaries of India.

33. THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE FINANCIAL YEAR

During the year under review, the Company has not made any application before the National Company Law Tribunal under Insolvency and

Bankruptcy Code, 2016 for recovery of outstanding loans against customer and there is no pending proceeding against the Company under Insolvency and Bankruptcy Code, 2016.

34. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF DURING THE FINANCIAL YEAR

Disclosure under the heading is not applicable to the Company, during the financial year under review.

35. ACKNOWLEDGEMENT

The Directors wish to place on record their appreciation for the unwavering trust and confidence reposed by the shareholders in the management and governance of the Company.

Further, the Board acknowledges the valuable contributions and support received from various regulatory agencies, customers, suppliers, and all other stakeholders who have played a vital role in the successful conduct of the Company's business. Your continued support and collaboration remain the cornerstone of our progress, and we look forward to strengthening these relationships in the years to come.

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

CONCORD BIOTECH LIMITED

SUDHIR VAID

Place: Ahmedabad Chairman & Managing Director Date: May 29, 2026 DIN:00055967